Table 1 Summary of baseline demographics and disease characteristics (full analysis set)
Characteristic | Tofacitinib → placebo group | Placebo → placebo group |
|---|---|---|
|  | (N = 97) | (N = 51) |
Mean (SD) age, years | 51.86 (12.68) | 47.25 (11.84) |
Sex, n (%) | Â | Â |
 Male | 22 (22.7) | 15 (29.4) |
 Female | 75 (77.3) | 36 (70.6) |
Race, n (%) | Â | Â |
 White | 90 (92.8) | 49 (96.1) |
 Asian | 3 (3.1) | 1 (2.0) |
 Black | 3 (3.1) | 0 |
 Other | 1 (1.0) | 1 (2.0) |
Mean (SD) body mass index, kg/m2 | 28.71 (6.16) | 28.11 (7.13) |
Mean (SD) duration of rheumatoid arthritis | 8.67 (7.49) | 8.25 (7.94) |
Prior corticosteroid use, n (%) | Â | Â |
 Yes | 50 (51.5) | 21 (41.2) |
 No | 47 (48.5) | 30 (58.8) |
Prior DMARD use, n (%) | Â | Â |
 Yes | 94 (96.9) | 47 (92.2) |
 No | 3 (3.1) | 4 (7.8) |
Prior NSAID use, n (%) | Â | Â |
 Yes | 73 (75.3) | 35 (68.6) |
 No | 24 (24.7) | 16 (31.4) |
Prior methotrexate use, n (%) | Â | Â |
 Yes | 87 (89.7) | 47 (92.2) |
 No | 10 (10.3) | 4 (7.8) |
Mean (SD) erythrocyte sedimentation rate, mm/h | 45.34 (17.43) | 47.08 (23.83) |
Mean (SD) C-reactive protein, mg/L | 18.37 (22.57) | 15.66 (22.55) |
Rheumatoid factor, n (%) | Â | Â |
 Positive | 69 (71.1) | 34 (66.7) |
 Negative | 28 (28.9) | 17 (33.3) |
Mean (SD) DAS28-3(CRP) | 5.27 (0.95) | 5.31 (0.81) |
Mean (SD) DAS28-4(CRP) | 5.50 (1.05) | 5.56 (0.93) |
Mean (SD) Patient Assessment of Arthritis Pain | 53.98 (22.77) | 57.45 (21.04) |
Mean (SD) Patient Global Assessment of Arthritis | 56.13 (23.78) | 58.67 (21.70) |
Mean (SD) Physician Global Assessment of Arthritis | 57.24 (17.83) | 55.22 (17.11) |
Mean (SD) tender/painful joint counts | 20.41 (11.63) | 23.43 (13.34) |
Mean (SD) swollen joint counts | 12.48 (6.76) | 12.67 (6.91) |
Mean (SD) HAQ-DI | 1.49 (0.65) | 1.41 (0.69) |